CS
SION

Candriam SCA’s Sionna Therapeutics SION Stock Holding History

Candriam SCA’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.49M Buy
+236,813
New +$9.04M 0.05% 286

Other funds holding SION

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Candriam SCA's SION Position: Q1 2026 in Review

Candriam SCA opened a new position in Sionna Therapeutics (SION) in Q1 2026: 236,813 shares worth $9.49M. The stake represents 0.05% of the portfolio and ranks #286 among its holdings.

122 funds tracked by Wall St. Rank hold SION as of Q1 2026.

  • Candriam SCA held 236,813 shares of Sionna Therapeutics worth $9.49M as of Q1 2026.
  • Sionna Therapeutics was a new Candriam SCA position in Q1 2026.
  • Sionna Therapeutics made up 0.05% of Candriam SCA's portfolio in Q1 2026, its #286 holding.
  • 122 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q1 2026.

Based on Candriam SCA's 13F filing for Q1 2026, filed 30 Apr 2026.